Navigation Links
Antifungal Drugs: Technologies and Global Markets
Date:8/29/2012

NEW YORK, Aug. 29, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antifungal Drugs: Technologies and Global Markets

http://www.reportlinker.com/p0196570/Antifungal-Drugs-Technologies-and-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

INTRODUCTION

STUDY GOALS AND OBJECTIVES BCC's goal in conducting this study was to determine the current status of the global human antifungal market and assess its growth potential over the five-year period from 2011 to 2016. This report covers approved human therapeutics with a heavy focus on therapeutics in early development. These new molecular and biological entities are from traditional pharmaceutical sources, naturally derived synthetic chemicals and biological sources as well as the "herbal natural folk medicine" marketplace. If an approved or well-known medicine is being studied in combination with another molecular entity, it is considered a "new therapy" and often has been included for review. New drug and patent applications are presented as the study focuses on new methods of drug administration, drug clinical trials, and discovery and development.

It should be noted that there is a strong emphasis on early research given the critical need for new and more effective medicines; hence, BCC is including a section of medicines intended for human utilization that are in the preclinical (animal) models of testing, and information on new and novel in vitro therapies. Greater than 98% of medicines at the preclinical level are terminated prior to their utilization in humans, and the research in this area is vast. We are limiting this research to therapies that depict a positive result or represent a very rare and novel approach worthy of further review from R&D groups.

Our key objective in this report is to present an in-depth analysis of the current human antifungal market and explore its future direction. In the last five years there has been a vast increase in the number of patent applications filed in this area. Between 1990 and 1999 there were six U.S. patents granted—evidence of the evolution of drug resistance and an increasing mortality rate.[1],[2]

REASONS FOR DOING THIS STUDY Fungi are highly resistant microbiological eukaryotic microorganisms. In other words, they are becoming drug-resistant to the approved compounds and some therapies later in clinical development. The therapies are designed to eradicate them through the various antifungal mechanisms of action, such as disrupting reproductive capabilities, destroying cell walls, or modifying fungal DNA and cell functioning. It is a given fact that infestations in humans, animals, plants and the environment are on the rise, with many having lethal consequences in both the immunocompetent and the immunocompromised. That being the case, BCC was particularly interested in examining the antifungal market growth of developing products depicting efficacy. We are including data regarding the market shift for those products that are now relegated to over-the-counter (OTC) status previously having only been provided by prescription, and to identify new antifungal research, development, new drug applications and novel approaches to the market.

Previously, BCC examined the antifungal market in its 2003 report, PHM029A ? The Market for Antifungal Drugs, in PHM029B ? Global Markets for Antifungal Agents and in PHM029C ? Antifungal Drugs: Technologies and Global Markets. Due to the rapidly changing market, BCC chose to reexamine the marketplace through another analysis and project its new growth potential. Additionally, PHM029A focused only on human fungal diseases and associated antifungals; PHM029B incorporated the marketplace for antifungals in the veterinary, agricultural and environmental industries; and PHM029C focused on human therapeutics with an intensive focus on human therapeutics in the developmental pipeline. PHM029D is an update of PHM029C.

INTENDED AUDIENCE

This report was prepared as a study of the global antifungal marketplace based on fungal infections and infestations with a focus on human therapeutics. Information is presented on the antifungal industry in general, pharmaceuticals and chemical agents, new technology within the market, new and novel drug applications and market-related issues—in many cases actual revenue is given for the period of 2010 and 2011, with projections of trends and compound annual growth rates (CAGRs) 2011 through 2016.

This study will be of significant interest to hospitals, pharmacies, pharmaceutical companies, biopharmaceutical researchers, pharmaceutical company marketing executives, contract research organizations (CROs), chemists, physicians, nurses, physician assistants, pharmaceutical directors, product managers and representatives, all manner of institutional directors ranging from nursing homes and schools to long-term-care facilities both public and private. It will also be of interest to biologists and those interested in the field of mycology.

SCOPE OF REPORT This study examines human applications both marketed and in the development of antifungal technologies. In an extensive analysis, BCC examines each market segment, presents its current market status, and presents various forecasts for growth over the next five years. Other factors such as Food and Drug Administration (FDA) restrictions, government legislation, fungal resistance, and changes in consumerism such as a greater demand for OTC medications and/or natural and alternative remedies are also highlighted. Our financial and sales analysis focuses on the available figures from 2010 to 2011, with estimates for 2016, including CAGR as a percentage.METHODOLOGY Through an extensive industry survey inclusive of online database searches of industry-specific data sources coupled with financial, trade, government and marketing database sources as well as interviews via correspondence or telephone with independent sources comprising companies, government agencies and academic experts, BCC was able to compile data to present our analysis of the antifungal market by market segment. INFORMATION SOURCES Of the companies and agencies surveyed, the majority were pharmaceutical or compound manufacturers. Additional information was supplied by known industry or trade sources. ANALYST CREDENTIALS Mary Anne Crandall is an expert industry analyst specializing in the pharmaceutical industry for over 20 years. She has completed several in-depth studies on various medical topics requiring both medical expertise and excellent knowledge of the pharmaceutical industry. Ms. Crandall has extensive knowledge in the medical field, has a M.S. in psychology and is currently working on a Ph.D.TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 1

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THIS STUDY 1

INTENDED AUDIENCE 2

SCOPE OF REPORT 2

METHODOLOGY 2

INFORMATION SOURCES 2

ANALYST CREDENTIALS 3

RELATED BCC REPORTS 3

BCC ONLINE SERVICES 3

DISCLAIMER 3

CHAPTER 2 SUMMARY 5

SUMMARY TABLE GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL THERAPEUTICS

BY GEOGRAPHIC REGION, THROUGH 2016 ($ MILLIONS) 5

SUMMARY FIGURE GLOBAL SALES OF HUMAN ANTIFUNGALS, 2011 AND 2016 ($ MILLIONS) 6

CHAPTER 3 OVERVIEW 8

HISTORY AND CURRENT STATE OF ANTIFUNGALS 8

TYPES OF PATHOGENIC FUNGI 9

DEFINITION OF THE INDUSTRY 9

CONCEPTS IN THE INDUSTRY 9

IMPORTANCE OF THE INDUSTRY 10

PRODUCT LIFE CYCLES 11

TABLE 1 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG 12

DEVELOPMENT OF ANTIFUNGALS 12

FDA-APPROVED ANTIFUNGALS 13

AZOLE ANTIFUNGALS 13

ECHINOCANDINS 13

POLYENES 13

ALLYLAMINES 13

MISCELLANEOUS ANTIFUNGALS 14

FUTURE DEVELOPMENTS 14

HUMAN CLINICAL DEVELOPMENT, 2009 TO 2011 14

NEW DRUG ACTIVITY 15

TABLE 2 CLINICAL TRIALS OF ALL NEW DRUG THERAPIES AND COMBINATIONS BY ALL

DATE FIELDS, 2009-2011 16

TABLE 3 SELECTED GLOBAL CLINICAL TRIALS OF ALL NEW DRUG THERAPIES THAT

EITHER ARE COMPLETED OR ESTIMATED TO BE COMPLETED BETWEEN 2009 AND 2012 16

ACTIVE OR COMPLETED STUDIES POSTED OR UPDATED, 2009 TO 2011 16

TABLE 4 ACTIVE OR COMPLETED STUDIES, 2009-2011 16

CHAPTER 4 INTRODUCTION TO INDUSTRY APPLICATIONS OF ANTIFUNGAL MEDICINAL

THERAPEUTICS 20

SCOPE OF APPLICATIONS: HUMAN HEALTHCARE 20

HUMAN FUNGAL INFECTIONS 21

RISK FACTORS FOR DEVELOPING FUNGAL INFECTIONS 22

TABLE 5 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS 23

FUNGAL SPECIES THAT CAUSE INFECTION IN HUMANS 24

Candidiasis 24

Cutaneous Candidiasis 26

Chronic Mucocutaneous Candidiasis 26

GI Tract Candidiasis 27

Respiratory Tract Candidiasis 27

Genitourinary Tract Candidiasis 27

Hepatosplenic Candidiasis 27

Systemic Candidiasis 27

Candidemia 28

Disseminated Candidiasis 28

Aspergillosis 29

Blastomycosis 30

Coccidioidomycosis 30

Cryptococcosis 31

Dermatophytosis 32

Histoplasmosis 33

Onychomycosis 34

Paracoccidioidomycosis 35

Pseudallescheriasis 35

Sporotrichosis 36

Zygomycosis 36

TABLE 6 INCIDENCE OF COMMON FUNGAL DISEASES 38

MORE RARE FUNGAL INFECTIONS AND DISORDERS 38

Literature Review 39

FUNGAL DRUG RESISTANCE 40

CURRENT DRUG RESISTANCE TOPICS: A GLOBAL VIEW 40

MDR SPECIES 41

Literature Review 43

TABLE 7 COMMON REASONS FOR FUNGAL RESISTANCE 44

STRATEGIES TO IMPROVE RESPONSE AND DECREASE MORTALITY 44

Literature Review 45

CHAPTER 5 HUMAN ANTIFUNGAL AGENTS 47

TABLE 8 GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL CONSUMPTION BY

PRODUCT TYPE, THROUGH 2016 ($ MILLIONS) 47

CLASSES OF ANTIFUNGALS 47

ECHINOCANDINS 47

Literature Review 48

AZOLES 48

Literature Review 49

POLYENES 49

Literature Review 49

OTHER 49

TABLE 9 GLOBAL ANTIFUNGAL PHARMACEUTICAL SALES: TRIAZOLES AND

ECHINOCANDINS VERSUS OTHER ANTIFUNGALS THROUGH 2016 ($ MILLIONS) 50

TABLE 10 PHARMACEUTICAL ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%) 50

FIGURE 1 PERCENTAGE OF RECOGNIZED ANTIFUNGAL DRUGS (%) 50

TABLE 11 MAJOR ANTIFUNGAL AGENTS BY CLASS AND AVERAGE SALES PRICE PER

DOSAGE, 2009 52

TABLE 12 FUNGAL INFECTION AND TRADITIONAL PHARMACEUTICAL REMEDY 53

TABLE 13 TYPE OF CANDIDAL INFECTION AND PHARMACEUTICAL TREATMENT 54

SIDE EFFECTS 54

TABLE 14 LIFE-THREATENING SIDE EFFECTS FROM ANTIFUNGAL PHARMACEUTICALS 56

OTC ANTIFUNGAL PREPARATIONS 56

TABLE 15 COMMON FUNGAL INFECTIONS AND OTC ROUTES OF ADMINISTRATION 58

NATURAL ANTIFUNGAL REMEDIES 58

TYPES OF NATURAL ANTIFUNGAL REMEDIES 59

Herbal Remedies 59

Enzyme-based Antifungal Agents 60

TABLE 16 COMMON NATURAL ANTIFUNGALS 61

SUMMARY OF SELECTED NATURAL ANTIFUNGALS 62

Aloe 62

Literature Review 63

Curcumin 63

Literature Review 64

Mint 64

Literature Review 64

Wild Marjoram 65

Literature Review 65

Radish 65

Literature Review 66

Parnafungins 66

Literature Review 67

Ginseng 67

Literature Review 68

Walnut 68

Literature Review 68

Pau d'arco 68

Literature Review 69

Garlic 69

Literature Review 69

Grapefruit Seed 70

Literature Review 70

Olive Leaf 70

Literature Review 70

Goldenseal 71

Literature Review 71

Oregano 71

Literature Review 71

Tea Tree 72

Literature Review 72

NATURAL REMEDIES IN EARLIER DEVELOPMENT 72

Literature Review 72

LABORATORY TESTING AND HISTOPATHOLOGY FOR FUNGAL INFECTIONS IN

HUMANS 74

Specimen Examination 74

Cultures 75

Blood Serology 75

ALTERNATIVE HEALTHCARE APPROACHES TO TESTING AND DIAGNOSIS OF

FUNGAL INFECTIONS 75

CAM Testing and Specialized Laboratories 75

Questionnaire for Symptoms 76

CHAPTER 6 COMMON ENVIRONMENTAL FUNGI 78

MOLDS AND THE HUMAN ISSUES THEY PRODUCE 78

WHY ENVIRONMENTAL MOLD IS A UNIQUE PROBLEM 79

HEALTH RISKS DUE TO ENVIRONMENTAL FUNGI AND MOLD 80

TABLE 17 COMMON HEALTH SYMPTOMS BASED ON ENVIRONMENTAL FUNGI AND MOLDS 81

TABLE 18 RISK FACTORS ASSOCIATION WITH ENVIRONMENTAL MOLD REACTIONS 81

TABLE 19 COMMON SOURCE LOCATIONS FOR ENVIRONMENTAL MOLDS 82

ENVIRONMENTAL MOLDS 82

ALTERNARIA 82

Literature Review 83

ASPERGILLUS 83

Literature Review 84

CLADOSPORIUM 84

Literature Review 85

PENICILLIUM 85

Literature Review 86

EUROTIUM 87

Literature Review 87

RHIZOPUS 87

Literature Review 87

MUCOR 88

Literature Review 88

GEOTRICHUM 88

Literature Review 88

FUSARIUM 89

Literature Review 89

STACHYBOTRYS 90

Literature Review 90

WALLEMIA 90

Literature Review 90

TRICHOTHECIUM 91

Literature Review 91

SCOPULARIOPSIS BREVICAULIS 91

Literature Review 91

SCYTALIDIUM DIMIDIATUM 92

Literature Review 92

TRICHODERMA 92

Literature Review 93

PAECILOMYCES VARIOTII 93

Literature Review 93

CHAPTER 7 GOVERNMENT REGULATORY AGENCIES AND PROFESSIONAL ASSOCIATIONS 96

GOVERNMENT REGULATIONS 96

FDA 96

TABLE 20 ANTIFUNGAL WARNING LETTERS FOR THE HUMAN SEGMENT FROM THE FDA

TO MANUFACTURERS, 1997-2011 97

EPA 102

USDA 103

FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS 104

PROFESSIONAL ASSOCIATIONS 104

MEDICAL AND VETERINARY ASSOCIATIONS 104

AGRICULTURAL ASSOCIATIONS 104

OTHER ENVIRONMENTAL ASSOCIATIONS 104

CHAPTER 8 ANTIFUNGAL COMPANIES 107

HUMAN HEALTHCARE 107

PHARMACEUTICAL MANUFACTURERS 107

TABLE 21 MAJOR GLOBAL MANUFACTURERS OF HUMAN ANTIFUNGAL PHARMACEUTICALS 107

FIGURE 2 GLOBAL ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS BY COUNTRY (%) 107

MAJOR PHARMACEUTICAL MANUFACTURER PROFILES 108

TABLE 22 COMPETITIVE MARKET SHARE BY PERCENT, 2011 (%) 109

FIGURE 3 COMPETITIVE MARKET SHARE BY PERCENT, 2011 (%) 109

Astellas Pharma, Inc. 109

Bayer HealthCare 110

Enzon Pharmaceuticals 110

Galderma Pharma SA/Galderma SA 110

Gilead Sciences, Inc. 111

Medicis Pharmaceutical Corp. 111

Novartis International AG 111

Pfizer, Inc. 112

Taro Pharmaceutical Industries, Ltd. 112

Teva Pharmaceutical Industries, Ltd. 112

OTC ANTIFUNGAL MANUFACTURERS 113

PHARMACEUTICAL OTC MARKET 113

TABLE 23 MAJOR HUMAN OTC ANTIFUNGAL MANUFACTURERS AND PRODUCTS 113

MAJOR PHARMACEUTICAL-BASED OTC MANUFACTURER PROFILES 114

Alva-Amco Pharmacal 114

Blaine Labs 114

Dartmouth Pharmaceuticals 115

Del Laboratories 115

Ganeden Biotech 115

Kramer Laboratories 115

Novartis International AG 116

Ortho McNeil 116

PEDiNOL Pharmacal, Inc. 116

Stiefel Laboratories 116

Tarmac Products 117

ALTERNATIVE OTC MANUFACTURERS 117

TABLE 24 COMMONLY AVAILABLE ALTERNATIVE ANTIFUNGALS 117

MAJOR ALTERNATIVE OTC MANUFACTURER PROFILES 118

AquaFlora 118

Crystal Star Herbal Nutrition 118

Enzymedica 118

Forest Herbs Research 119

Garden of Life 119

Michael's Naturopathic Programs 119

Nature's Plus 120

NOW Foods 120

Nutrition Now 120

PROSymbiotics 121

Pure Essence Laboratories 121

Rainbow Light 121

Renew Life 122

Solaray 122

Vitanica 122

CHAPTER 9 ANTIFUNGAL INDUSTRY 124

ANTIFUNGAL MARKET TRENDS: HUMAN HEALTHCARE 124

ACCELERATING ANTIFUNGAL DRUG DEVELOPMENT 124

TABLE 25 NEW PRESCRIPTION ANTIFUNGALS, 2005–JANUARY 2012 125

INCREASED TYPES OF TESTING 125

Need to Increase Use and Acceptance of Newer Drugs 126

EXPERIMENTAL RESEARCH: CLINICAL TRIALS PERFORMED AND SELECTED

PRECLINICAL AND IN VIVO STUDIES 126

A GENERAL OVERVIEW OF NON-PHARMACEUTICAL ANTIFUNGAL TECHNOLOGIES 127

Laser and Photodynamic Therapy 127

Studies 128

Literature Review 128

mAbs 128

Diagnostics and Assays 129

Literature Review 129

Computer Modeling Technology 130

Literature Review 130

R&D SECTION: AN OVERVIEW OF PRODUCTS IN DEVELOPMENT 130

TABLE 26 ANTIFUNGALS IN DEVELOPMENT 131

TRENDS IN CLASS USED AND ADMINISTRATION METHOD 132

TABLE 27 PHARMACEUTICAL ANTIFUNGALS BY ROUTE OF ADMINISTRATION, 2011 (%) 133

FIGURE 4 PHARMACEUTICAL ANTIFUNGALS BY ROUTE OF ADMINISTRATION, 2011 (%) 133

TABLE 28 GLOBAL MARKET FORECAST FOR ANTIFUNGAL PHARMACEUTICAL PRODUCTS BY

ROUTE OF ADMINISTRATION, THROUGH 2016 ($ MILLIONS) 133

UTILIZATION OF OTC AND NATURAL/ALTERNATIVE ANTIFUNGAL AGENTS 134

Shifting Market From Prescription to OTC 134

Market Demand for OTC Products 134

CHAPTER 10 PATENT ANALYSIS 136

PURPOSE OF A PATENT ANALYSIS 136

DUE CARE IN REVIEWING THE PATENT ANALYSIS 136

NEW ANTIFUNGAL PATENTS ISSUED 136

TABLE 29 U.S. ANTIFUNGAL PATENT TRENDS, 1990-2009 (NUMBER OF PATENTS ISSUED) 137

TABLE 30 NEW U.S. ANTIFUNGAL PATENTS ISSUED, 2007–2012 137

TABLE 31 ASSIGNEES OF TWO OR MORE U.S. PATENTS FOR ANTIFUNGAL PRODUCTS,

2007-2011 140

TABLE 32 U.S. PATENT TRENDS BY COUNTRY, 2007-2011 (QUANTITY/%) 140

FIGURE 5 U.S. PATENT TRENDS BY COUNTRY, 2007-2011 (%) 141

TRENDS IN PATENT APPLICATIONS 141

TABLE 33 U.S. PATENT APPLICATIONS BY ANTIFUNGAL MECHANISM OF ACTION, 2007-2011 142

FIGURE 6 U.S. PATENT APPLICATIONS BY ANTIFUNGAL MECHANISM OF ACTION, 2007

THROUGH 2011 (%) 142

TABLE 34 NEW U.S. PATENT APPLICATIONS, 2007-2011 143

TABLE 35 RECENT TRENDS IN PATENT APPLICATIONS FOR ANTIFUNGALS BY MECHANISM

OF ACTION, 2007-2011 149

TABLE 36 U.S. PATENT APPLICATION TRENDS BY COUNTRY, 2007-2011 149

FIGURE 7 U.S. ANTIFUNGAL PATENT APPLICATIONS BY COUNTRY 2007-2011 (%) 149

PATENT EXPIRATIONS 150

TABLE 37 PATENT EXPIRATIONS 2006–2018 150

CHAPTER 11 APPENDIX 153

TABLE 38 PHARMACEUTICAL COMPANIES 153

LIST OF TABLES

SUMMARY TABLE GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL THERAPEUTICSBY GEOGRAPHIC REGION, THROUGH 2016 ($ MILLIONS) 5TABLE 1 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG 12TABLE 2 CLINICAL TRIALS OF ALL NEW DRUG THERAPIES AND COMBINATIONS BY ALLDATE FIELDS, 2009-2011 16TABLE 3 SELECTED GLOBAL CLINICAL TRIALS OF ALL NEW DRUG THERAPIES THAT EITHERARE COMPLETED OR ESTIMATED TO BE COMPLETED BETWEEN 2009 AND 2012 16TABLE 4 ACTIVE OR COMPLETED STUDIES, 2009-2011 16TABLE 5 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS 23TABLE 6 INCIDENCE OF COMMON FUNGAL DISEASES 38TABLE 7 COMMON REASONS FOR FUNGAL RESISTANCE 44TABLE 8 GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL CONSUMPTION BYPRODUCT TYPE, THROUGH 2016 ($ MILLIONS) 47TABLE 9 GLOBAL ANTIFUNGAL PHARMACEUTICAL SALES: TRIAZOLES ANDECHINOCANDINS VERSUS OTHER ANTIFUNGALS THROUGH 2016 ($ MILLIONS) 50TABLE 10 PHARMACEUTICAL ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%) 50TABLE 11 MAJOR ANTIFUNGAL AGENTS BY CLASS AND AVERAGE SALES PRICE PER DOSAGE,2009 52TABLE 12 FUNGAL INFECTION AND TRADITIONAL PHARMACEUTICAL REMEDY 53TABLE 13 TYPE OF CANDIDAL INFECTION AND PHARMACEUTICAL TREATMENT 54TABLE 14 LIFE-THREATENING SIDE EFFECTS FROM ANTIFUNGAL PHARMACEUTICALS 56TABLE 15 COMMON FUNGAL INFECTIONS AND OTC ROUTES OF ADMINISTRATION 58TABLE 16 COMMON NATURAL ANTIFUNGALS 61TABLE 17 COMMON HEALTH SYMPTOMS BASED ON ENVIRONMENTAL FUNGI AND MOLDS 81TABLE 18 RISK FACTORS ASSOCIATION WITH ENVIRONMENTAL MOLD REACTIONS 81TABLE 19 COMMON SOURCE LOCATIONS FOR ENVIRONMENTAL MOLDS 82TABLE 20 ANTIFUNGAL WARNING LETTERS FOR THE HUMAN SEGMENT FROM THE FDA TOMANUFACTURERS, 1997-2011 97TABLE 21 MAJOR GLOBAL MANUFACTURERS OF HUMAN ANTIFUNGAL PHARMACEUTICALS 107TABLE 22 COMPETITIVE MARKET SHARE BY PERCENT, 2011 (%) 109TABLE 23 MAJOR HUMAN OTC ANTIFUNGAL MANUFACTURERS AND PRODUCTS 113TABLE 24 COMMONLY AVAILABLE ALTERNATIVE ANTIFUNGALS 117TABLE 25 NEW PRESCRIPTION ANTIFUNGALS, 2005–JANUARY 2012 125TABLE 26 ANTIFUNGALS IN DEVELOPMENT 131TABLE 27 PHARMACEUTICAL ANTIFUNGALS BY ROUTE OF ADMINISTRATION, 2011 (%) 133TABLE 28 GLOBAL MARKET FORECAST FOR ANTIFUNGAL PHARMACEUTICAL PRODUCTS BYROUTE OF ADMINISTRATION, THROUGH 2016 ($ MILLIONS) 133TABLE 29 U.S. ANTIFUNGAL PATENT TRENDS, 1990-2009 (NUMBER OF PATENTS ISSUED) 137TABLE 30 NEW U.S. ANTIFUNGAL PATENTS ISSUED, 2007–2012 137TABLE 31 ASSIGNEES OF TWO OR MORE U.S. PATENTS FOR ANTIFUNGAL PRODUCTS,2007-2011 140TABLE 32 U.S. PATENT TRENDS BY COUNTRY, 2007-2011 (QUANTITY/%) 140TABLE 33 U.S. PATENT APPLICATIONS BY ANTIFUNGAL MECHANISM OF ACTION, 2007-2011 142TABLE 34 NEW U.S. PATENT APPLICATIONS, 2007-2011 143TABLE 35 RECENT TRENDS IN PATENT APPLICATIONS FOR ANTIFUNGALS BY MECHANISMOF ACTION, 2007-2011 149TABLE 36 U.S. PATENT APPLICATION TRENDS BY COUNTRY, 2007-2011 149TABLE 37 PATENT EXPIRATIONS 2006–2018 150TABLE 38 PHARMACEUTICAL COMPANIES 153

LIST OF FIGURES

SUMMARY FIGURE GLOBAL SALES OF HUMAN ANTIFUNGALS, 2011 AND 2016 ($ MILLIONS) 6

FIGURE 1 PERCENTAGE OF RECOGNIZED ANTIFUNGAL DRUGS (%) 50

FIGURE 2 GLOBAL ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS BY COUNTRY (%) 107

FIGURE 3 COMPETITIVE MARKET SHARE BY PERCENT, 2011 (%) 109

FIGURE 4 PHARMACEUTICAL ANTIFUNGALS BY ROUTE OF ADMINISTRATION, 2011 (%) 133

FIGURE 5 U.S. PATENT TRENDS BY COUNTRY, 2007-2011 (%) 141

FIGURE 6 U.S. PATENT APPLICATIONS BY ANTIFUNGAL MECHANISM OF ACTION, 2007

THROUGH 2011 (%) 142

FIGURE 7 U.S. ANTIFUNGAL PATENT APPLICATIONS BY COUNTRY 2007-2011 (%) 149

To order this report:Drug_and_Medication Industry: Antifungal Drugs: Technologies and Global Markets

Nicolas Bombourg

Reportlinker

Email: nicolasbombourg@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others
2. Genitourinary Drugs: Technologies and Global Markets
3. Antithrombotic/Anticoagulant Drugs: World Market 2012-2022
4. Ophthalmic Drugs: World Market Prospects 2012-2022
5. Cleveland Clinics 2012 Medical Innovation Summit Highlights Orthopaedic Technologies
6. Breast Cancer Diagnostic and Drug Technologies: Global Markets
7. ARAMARK Healthcare Technologies Taps Robert Steele to Lead ReMedPar
8. Montmed to Participate in 2013 Advanced Technologies and Treatments for Diabetes Conference
9. U.S. Navy Awards Multi-Million Dollar Contract to Innovation for Pharmacy Automation Technologies
10. Technologies Impacting the Future of Healthcare
11. ECRI Institute Helps Hospitals Design Spaces for Current and Future Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product ... Photo - http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
(Date:5/3/2016)... LAKE OSWEGO, Ore. , May 3, 2016 /PRNewswire/ ... about the importance of extending care beyond the implant ... Scientific Sessions, May 4-7 in San Francisco ... tasked with continually delivering the highest quality of patient ... ensuring patients are cared for each and every tomorrow," ...
(Date:5/3/2016)... -- Intec Pharma Ltd. (NASDAQ: ... announced the appointment of Pnina Strauss-Levy as ... Strauss-Levy has 15 years of experience in clinical research ... record, having supported the advancement of several products through ... the United States and ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... Warren L. Smith M.D. , There is a ... plagued people since the beginning of recorded medical history, and in spite of ... It's not just a matter of inconvenience; bladder infections cost us billions of dollars ...
(Date:5/4/2016)... ... May 04, 2016 , ... Mediware Information ... therapy software application that helps blood and marrow transplant (BMT) programs meet compliance ... launch, Mediware has continued to enhance core application features. These enhancements are designed ...
(Date:5/4/2016)... ... 04, 2016 , ... DESCO Medical Service, also known as ... sterilization service and sales company located in Pennsylvania. The terms of the deal ... asset management services to the medical and academic research industries. The acquisition will ...
(Date:5/4/2016)... ... ... Fertility Centers of New England announced today the opening of their newest ... convenient access to care for patients seeking fertility treatment in Maine. “We are delighted ... in Portland,” said Fertility Centers of New England President and CEO, Joseph A. Hill, ...
(Date:5/4/2016)... ... May 04, 2016 , ... Vasont Systems, ... Universal Integrator (VUI) extension supports the latest release of Adobe FrameMaker, Release 2015. ... interlace the process of creating, editing and storing XML. , The ...
Breaking Medicine News(10 mins):